Table V.

OR per genotype of rs11668344 (BRSK1) and CED score on reduced ovarian function, based on prevalence in three cohorts.

	genotype AA		genotype AG		genotype GG
CED in mg/m2	n (%)	OR (95% CI)	n (%)	OR (95% CI)	n (%)	OR (95% CI)
0	51 (40.8)	1 (ref)	36 (40.0)	0.97 (0.63–1.48)	14 (31.8)	0.68 (0.35–1.30)
>0–4000	19 (37.3)	0.86 (0.48–1.53)	19 (38.8)	0.92 (0.51–1.64)	5 (29.4)	0.60 (0.20–1.82)
≥4000–8000	36 (69.2)	3.26 (1.95–5.46)	36 (66.7)	3.48 (2.07–5.87)	7 (43.8)	1.13 (0.41–3.14)
≥8000	43 (58.1)	2.01 (1.31–3.08)	62 (77.5)	5.00 (3.27–7.63)	18 (81.8)	6.53 (2.36–18.05)

n (%) represents the number of cases with reduced ovarian function (% of total) within each genotype group. OR (95% CI) calculated based on the prevalence of a reduced ovarian function for every genotype and every CED category compared to the prevalence of a reduced ovarian function for survivors with a AA genotype treated without alkylating agents.